Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Getting GLP-1 medication in Vermont is easier than most people expect. Whether you live in Addison or a smaller town, the process is the same: fill out a quick health form, connect with a licensed physician, and receive your FDA-approved medication at home. No complicated paperwork, no specialist referrals, no long waits.
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the same FDA-approved drugs prescribed at top clinics — just made accessible through a simpler process. The STEP 1 trial (NEJM, 2021) demonstrated 15.3% mean weight loss with semaglutide; the SURMOUNT-1 trial (NEJM, 2022) demonstrated 22.5% mean weight loss with tirzepatide. Anyone who qualifies in Vermont can start today.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Vermont supports telehealth prescribing, which means your physician can legally prescribe GLP-1 medications online without an in-person visit. All VT-licensed providers in our network are fully compliant with state and federal regulations — making the process simple, legal, and safe for every Vermont patient.
Select your Vermont city to get started with a licensed GLP-1 provider. The process is just as simple in every city.
GLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
Vermont authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Vermont.
The simple 3-step GLP-1 process works in every neighboring state and across all 50 states nationwide — no matter where you live.
Licensed telehealth GLP-1 care is available statewide. Select a city to begin your clinical assessment with a state-licensed, board-certified physician.
Local weight loss and GLP-1 providers serving the Vermont area, based on Google Business listings.
South Burlington, VT
(802) 234-1277
5/5 ★ (5 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. The process is deliberately simple. You fill out a brief health form (about 5 minutes), a VT-licensed physician reviews it and conducts a telehealth consultation, and if eligible, your GLP-1 medication ships directly to your home. Most people complete the entire initial process in under 15 minutes.
Not at all. The Vermont application is written in plain, accessible language. Your physician will explain everything clearly in simple terms during your consultation — including what to expect from your medication, how to use it, and how to track your progress.
A VT-licensed physician reviews your form and contacts you to complete a brief consultation — usually within 24-48 hours. If you qualify, your prescription is issued immediately and sent to a licensed pharmacy the same day. Your medication typically arrives within 3-5 business days.
Any adult in Vermont can complete the free eligibility check. GLP-1 medications are typically prescribed for adults with a BMI ≥30, or ≥27 with a weight-related health condition. Your physician will determine if GLP-1 therapy is appropriate for your individual situation — simply and clearly.
Yes. The simplicity of the online process does not compromise quality. You are working with board-certified, VT-licensed physicians who follow the same clinical standards as any specialist clinic. All medications are sourced from licensed US pharmacies. Simple means efficient — not inferior.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
